Patents by Inventor Joe A. Tran
Joe A. Tran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945808Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.Type: GrantFiled: June 15, 2022Date of Patent: April 2, 2024Assignee: Dart Neuroscience, LLCInventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
-
Publication number: 20240027157Abstract: A weapon usage monitoring system that monitors information about at least a first weapon and a second weapon includes a mobile networking hub, a first weapon response device, a second weapon response device and an edge compute resource. The mobile networking hub can provide a local area network (LAN). The first weapon response device can have a first sensor that senses first weapon response data about the first weapon. The first weapon response device can communicate the first weapon response data to the mobile networking hub. The second weapon response device can have a second sensor that senses second weapon response data about the second weapon. The second weapon response device can communicate the second weapon response data to the mobile networking hub. An edge compute resource can aggregate the first and second weapon response data from the mobile networking hub into aggregated weapon response data.Type: ApplicationFiled: September 28, 2023Publication date: January 25, 2024Applicant: Armaments Research Company Inc.Inventors: Michael John Canty, Kyle William Broadway, Isaac E. Peachin, Vikas Arun, Joe Tran Lucas, Michael David Pelton, Kiran Singh Sahni, Joshua Haynes, William Deng
-
Publication number: 20240018161Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.Type: ApplicationFiled: October 6, 2021Publication date: January 18, 2024Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Andrew DINH, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Paul KRENITSKY, Mark Thomas MILLER, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Lino VALDEZ, Jinglan ZHOU
-
Publication number: 20230382925Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.Type: ApplicationFiled: October 6, 2021Publication date: November 30, 2023Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Timothy A. DWIGHT, Lev Tyler Dewey FANNING, Bryan A. FRIEMAN, Peter GROOTENHUIS, Anton V. GULEVICH, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Paul KRENITSKY, Vito MELILLO, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Johnny UY, Lino VALDEZ, Jinglan ZHOU
-
Publication number: 20230374038Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of mediated diseases, such as cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and therapies comprising such modulators, and processes and intermediates for making such modulators.Type: ApplicationFiled: October 6, 2021Publication date: November 23, 2023Inventors: Jason MCCARTNEY, Alexander Russell ABELA, Sunny ABRAHAM, Corey Don ANDERSON, Vijayalaksmi ARUMUGAM, Jaclyn CHAU, Jeremy CLEMENS, Thomas CLEVELAND, Timothy Richard COON, Timothy A. DWIGHT, Bryan A. FRIEMAN, Peter GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Paul KRENITSKY, Mark Thomas MILLER, Prasuna PARASELLI, Fabrice PIERRE, Alina SILINA, Joe A. TRAN, Jinglan ZHOU
-
Publication number: 20230295178Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.Type: ApplicationFiled: September 2, 2022Publication date: September 21, 2023Inventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
-
Publication number: 20230144411Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.Type: ApplicationFiled: June 15, 2022Publication date: May 11, 2023Inventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
-
Patent number: 11434247Abstract: Substituted furanopyrimidine chemical entities of Formula (I): wherein Ra has any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by PDE1 activity or dopaminergic signaling; treating neurological disorders, CNS disorders, dementia, neurodegenerative diseases, and trauma-dependent losses of function; treating stroke, including cognitive and motor deficits during stroke rehabilitation; facilitating neuroprotection and neurorecovery; enhancing the efficiency of cognitive and motor training, including animal skill training protocols; and treating peripheral disorders, including cardiovascular, renal, hematological, gastroenterological, liver, cancer, fertility, and metabolic disorders.Type: GrantFiled: November 26, 2018Date of Patent: September 6, 2022Assignee: Dart Neuroscience LLCInventors: Brett Bookser, Iriny Botrous, Aaron Burns, DeMichael Chung, Brian Dyck, Andrew Kleinke, Dange Vijay Kumar, Margaret McCarrick, Nicholas Raffaele, Joe Tran, Michael Weinhouse
-
Patent number: 11365191Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.Type: GrantFiled: February 26, 2019Date of Patent: June 21, 2022Assignee: Dart NeuroScience, LLCInventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
-
Publication number: 20210340127Abstract: Substituted cyclohexyl chemical entities of Formula (I): wherein Ra, G, and Rb have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive therapies; modulating and treating disorders mediated by nociceptin activity or dopamine signaling; treating neurological disorders, neurodegenerative diseases, depression, and schizophrenia; enhancing the efficiency of cognitive and motor training; and treating peripheral disorders, including renal, respiratory, gastrointestinal, liver, genitourinary, metabolic, and inflammatory disorders.Type: ApplicationFiled: February 26, 2019Publication date: November 4, 2021Inventors: Jillian Basinger Thompson, Brett C. Bookser, Scott Burley, Pablo Garcia-Reynaga, Andrew Hudson, Marco Peters, Benjamin Pratt, Aaron Thompson, Joe Tran, Lino Valdez
-
Patent number: 9721828Abstract: A method of filling STI trenches with dielectric with reduced particle formation. A method of depositing unbiased STI oxide on an integrated circuit during STI trench fill that reduces STI defects during STI CMP.Type: GrantFiled: December 3, 2014Date of Patent: August 1, 2017Assignee: TEXAS INSTRUMENTS INCORPORATEDInventors: Andrew Brian Nelson, Richard A. Stice, Joe Tran
-
Patent number: 9303033Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.Type: GrantFiled: September 13, 2013Date of Patent: April 5, 2016Assignee: SENHWA BIOSCIENCES, INC.Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas Raffaele, Suchitra Ravula, David M. Ryckman
-
Publication number: 20150187635Abstract: A method of filling STI trenches with dielectric with reduced particle formation. A method of depositing unbiased STI oxide on an integrated circuit during STI trench fill that reduces STI defects during STI CMP.Type: ApplicationFiled: December 3, 2014Publication date: July 2, 2015Inventors: Andrew Brian NELSON, Richard A. STICE, Joe TRAN
-
Publication number: 20140094448Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.Type: ApplicationFiled: September 13, 2013Publication date: April 3, 2014Applicant: SENHWA BIOSCIENCES, INC.Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas Raffaele, Suchitra Ravula, David M. Ryckman
-
Patent number: 8575177Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.Type: GrantFiled: November 15, 2010Date of Patent: November 5, 2013Assignee: Senhwa Biosciences, Inc.Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas B. Raffaele, Suchitra Ravula, David M. Ryckman
-
Patent number: 8481731Abstract: New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein X1, X2, X3, X4, Y1, Y2, A, R1, R2, R3, R4, m, n, p, and q are as defined herein, including stereoisomers, esters, and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof in a patient in need thereof.Type: GrantFiled: June 23, 2010Date of Patent: July 9, 2013Assignees: Boehringer Ingelheim International GmbH, Neurocrine Biosciences, Inc.Inventors: Joe A. Tran, Chen Chen
-
Patent number: 8367681Abstract: The invention provides compounds of general formula (I) that inhibit selected kinases (Pim and/or CK2 kinases) and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain infections and immunological disorders.Type: GrantFiled: May 20, 2010Date of Patent: February 5, 2013Assignee: Cylene Pharmaceuticals, Inc.Inventors: Mustapha Haddach, Joe Tran
-
Patent number: 8293729Abstract: New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.Type: GrantFiled: June 23, 2010Date of Patent: October 23, 2012Assignees: Boehringer Ingelheim International GmbH, Neurocrine Biosciences Inc.Inventors: Brian Dyck, Joe A. Tran, Junko Tamiya, Florence Jovic, Troy Vickers, Chen Chen, Nicole Harriott, Timothy Coon, Neil J. Ashweek
-
Publication number: 20110166116Abstract: New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R1, R2, R3, n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.Type: ApplicationFiled: June 23, 2010Publication date: July 7, 2011Applicants: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, NEUROCRINE BIOSCIENCES, INC.Inventors: Brian DYCK, Joe A. TRAN, Junko TAMIYA, Florence JOVIC, Troy VICKERS, Chen CHEN, Nicole HARRIOTT, Timothy COON, Neil J. ASHWEEK
-
Publication number: 20110152240Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.Type: ApplicationFiled: November 15, 2010Publication date: June 23, 2011Applicant: CYLENE PHARMACEUTICALS, INC.Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas B. Raffaele, Suchitra Ravula, David M. Ryckman